K

Kidswell Bio Corporation
TSE:4584

Watchlist Manager
Kidswell Bio Corporation
TSE:4584
Watchlist
Price: 245 JPY -3.92% Market Closed
Market Cap: ¥12.1B

Net Margin

4.3%
Current
Improving
by 33.3%
vs 3-y average of -29%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.3%
=
Net Income
¥281.2m
/
Revenue
¥6.6B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.3%
=
Net Income
¥281.2m
/
Revenue
¥6.6B

Peer Comparison

Country Company Market Cap Net
Margin
JP
Kidswell Bio Corporation
TSE:4584
12.1B JPY
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in Japan
Percentile
42st
Based on 6 917 companies
42st percentile
4.3%
Low
-122 700% — 2.9%
Typical Range
2.9% — 8.5%
High
8.5% — 63 031.4%
Distribution Statistics
Japan
Min -122 700%
30th Percentile 2.9%
Median 5.4%
70th Percentile 8.5%
Max 63 031.4%

Kidswell Bio Corporation
Glance View

Market Cap
12.1B JPY
Industry
Biotechnology

Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 39 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.

Intrinsic Value
584.5 JPY
Undervaluation 58%
Intrinsic Value
Price
K
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
4.3%
=
Net Income
¥281.2m
/
Revenue
¥6.6B
What is Kidswell Bio Corporation's current Net Margin?

The current Net Margin for Kidswell Bio Corporation is 4.3%, which is above its 3-year median of -29%.

How has Net Margin changed over time?

Over the last 3 years, Kidswell Bio Corporation’s Net Margin has increased from -5.9% to 4.3%. During this period, it reached a low of -62.2% on Sep 30, 2023 and a high of 4.9% on Jun 30, 2025.

Back to Top